
Tuesday, April 16, 2019—As published in the New England Journal of Medicine, positive results have been seen in a small study of pembrolizumab (Keytruda; Merck, Kenilworth, NJ) for treatment of …
Monday, April 01, 2019—The Food and Drug Administration (FDA) has approved cladribine tablets (Mavenclad; EMD Serono, Rockland, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) and…
Wednesday, March 27, 2019—The first drug to treat 3 phases of multiple sclerosis (MS), secondary-progressive MS (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome (CIS), has b…
March/April 2019—Sleep has a critical role in brain health and is an essential part of improving neurologic care for all of our patients.
March/April 2019—Telemedicine is acceptable to patients and clinicians in the continuum of clinic-to-in-home care and reduces barriers to care.
March/April 2019—Part 1: Untangling the complexity of dizziness and vertigo requires a careful history.
Friday, March 15, 2019—In a study published in Neurology, researchers at the Cleveland Clinic evaluated patients’ tolerance for potential risks of multiple sclerosis (MS) medications. Stu…
Thursday, March 07, 2019—In the 2-year CLARITY trial (NCT00213135), 47% of patients treated with cladribine tablets (CT) (EMD Serono; Rockland, MA) achieved no evidence of disease activity (NEDA) comp…
For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com
Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.
We use cookies to offer a better user experience and to analyze site traffic. To comply with the European General Data Protection Regulation (GDPR), we are implementing a cookie consent manager to provide residents of the EU/EEA with the ability to customize their cookies. Until this is available, your continued use of this site will be deemed as consent to use of cookies.
Continue »